Q4 2016 13F Holders as of 31 Dec 2016
-
Type / Class
-
Debt / NOTE 1.500%10/1
-
Number of holders
-
39
-
Total 13F principal, excl. options
-
339,236,012
-
Principal change
-
+24,849,000
-
Total reported value, excl. options
-
$399,582,215
-
Value change
-
+$28,890,823
-
Number of buys
-
17
-
Number of sells
-
-19
-
Price
-
$1.18
Significant Holders of BIOMARIN PHARMACEUTICAL INC - NOTE 1.500%10/1 as of Q4 2016
46 filings reported holding 09061GAF8 - BIOMARIN PHARMACEUTICAL INC - NOTE 1.500%10/1 as of Q4 2016.
BIOMARIN PHARMACEUTICAL INC - NOTE 1.500%10/1 has 39 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $339,236,012 of principal
.
Largest 10 bondholders include Linden Advisors LP ($46,709,000 of principal), Invesco Ltd. ($37,243,000 of principal), FRANKLIN RESOURCES INC ($29,700,000 of principal), ADVENT CAPITAL MANAGEMENT /DE/ ($27,377,000 of principal), SHENKMAN CAPITAL MANAGEMENT INC ($26,009,000 of principal), FMR LLC ($24,360,000 of principal), Calamos Advisors LLC ($19,264,000 of principal), ROYAL BANK OF CANADA ($17,592,000 of principal), LAZARD ASSET MANAGEMENT LLC ($15,537,000 of principal), and BANK OF AMERICA CORP /DE/ ($13,866,000 of principal).
This table shows the top 39 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.